Amgen's Strong Earnings Growth Attracts Investors

When it comes to investing in companies, even those with a good story can be high-risk investments. Loss-making companies can act like sponges for capital, making investors cautious about throwing good money after bad.

Amgen (NASDAQ:AMGN), on the other hand, is a profitable and growing company that has demonstrated impressive earnings per share growth (EPS) over the past year. From $12.31 to $16.17, Amgen's EPS soared by 31%, making it an attractive option for investors.

The company's revenue from operations did not account for all of its revenue in the previous 12 months, which may impact analysis of its margins. However, Amgen is growing revenues and EBIT margins improved by 3.4 percentage points to 34% over the last year, both great metrics for potential growth.

Amgen's management team has a significant stake in the company, worth $373m, which aligns their interests with those of shareholders. This level of insider ownership is impressive and suggests that management appreciates Amgen's strong earnings growth and has faith in its continuing strength.